Presentation slides for the ACIP meeting today are available here. Updates to clinical communication indicate that, while patients with a history of Guillain-Barre Syndrome (GBS) are eligible for any of the authorized vaccines, they should discuss with their clinical teams the availability of mRNA vaccines given the association of GBS with the J&J vaccine.
For the summary of the issues regarding giving booster vaccine doses to immunocompromised patients, see data from slide 15 onwards.
The Advisory Committee on Immunization Practices (ACIP) will meet with the CDC July 22, 2021 to discuss COVID-19 vaccine boosters for immunocompromised individuals and the association of the J&J vaccine with Guillain-Barre Syndrome. See the draft agenda here.
On July 13, 2021, the FDA issued a revision to the J&J COVID-19 vaccine fact sheets regarding the increased risk of Guillain-Barre Syndrome (GBS) with the vaccine. According to the announcement, the benefits still outweigh the risks for getting the vaccine and so far no causal association has been found. GBS is rare and has been associated with other vaccines, including the flu vaccine. GBS has not been associated with the mRNA vaccines, so far.
Go Retire Psychiatrist 